Clean product-level table
Quarterly product sales with standardized product names, company, ticker, indication, therapeutic area, reported category, currency, and quarter columns.
Quarterly pharmaceutical product sales database
Drug sales data, cleaned for investor analysis.
Quarterly pharmaceutical product sales from the world's leading pharma companies, standardized into a single database with an offline interactive dashboard.
Current edition includes Excel/CSV source data plus an offline interactive HTML dashboard.
27major pharma companies in the current build
550+tracked product lines and reported franchises
8quarters from 2024 Q2 through 2026 Q1
XLSXExcel workbook with USD and local-currency views
Pharma product sales database
Product-level revenue data without the enterprise platform overhead.
DrugSalesDB is a lightweight alternative for investors and analysts who need quarterly drug sales, launch tracking, and cross-company pharma revenue comparison without manually rebuilding tables from PDFs and investor appendices.
Designed for
Built for investors and pharma people who need the numbers in one place.
Instead of collecting product sales from dozens of investor presentations, annual reports, earnings releases, and SEC filings, DrugSalesDB brings everything together in a consistent format for analysis.
Biotech investors
Equity research
Pharmaceutical professionals
Business development & strategy
Healthcare consultants
Students preparing for pharma interviews
What you get
A practical spreadsheet for people who actually open spreadsheets.
The product is the workbook. The chart is there to make the data easier to feel, share, and inspect before you start filtering.
Source data in Excel/CSV
Use the workbook directly in Excel, Google Sheets, filters, pivot tables, charts, or your own analysis workflow.
Unified USD view
Directional USD conversions make cross-company ranking easier, while local-currency fields preserve company-reported context where it matters.
Interactive dashboard included
An offline HTML dashboard lets you search, filter, and compare product-sales momentum across companies and normalized therapeutic areas.
Historical quarterly data
The current edition tracks quarters from 2024 Q2 through 2026 Q1 where company disclosures make the data available.
Consistent analysis layer
Company-reported categories are kept, while normalized therapeutic areas make cross-company comparisons easier.
Companies included
Coverage across large-cap pharma and selected global specialists.
The current build includes 27 companies, including major US, European, and Japanese pharmaceutical companies.
- AbbVie
- Amgen
- Astellas Pharma
- AstraZeneca
- Bayer
- Bristol Myers Squibb
- Daiichi Sankyo
- Eli Lilly
- Gilead Sciences
- Johnson & Johnson
- Kyowa Kirin
- Merck & Co.
- Merck KGaA
- Novartis
- Novo Nordisk
- Ono Pharmaceutical
- Otsuka Holdings
- Pfizer
- Regeneron Pharmaceuticals
- Roche
- Sanofi
- Santen Pharmaceutical
- Shionogi
- Sumitomo Pharma
- Takeda
- Vertex Pharmaceuticals
- argenx
Included HTML dashboard
You get an offline tool like this with the download.
The screenshots below show the interactive HTML companion included with the product. It works offline and lets you search, filter by company or therapeutic area, and compare drug sales across the full paid dataset.
Rank by sales
The included dashboard ranks products by quarterly USD sales and helps you compare franchises across companies and therapeutic areas.
Product momentum view
The companion view makes launch ramps and product movement easier to spot before you dive into the Excel/CSV source data.
Sample download
Inspect the structure before buying.
The sample is intentionally small: six non-GLP rows with the full quarter structure from 2024 Q2 to 2026 Q1. It shows the schema without replacing the paid workbook.
| Company | Product | Area | 2024 Q2 | 2026 Q1 |
|---|---|---|---|---|
| Merck & Co. | Keytruda | Oncology | 7.27 | 7.91 |
| Johnson & Johnson | DARZALEX | Oncology | 2.88 | 3.96 |
| AbbVie | Skyrizi | Immunology | 3.21 | |
| Bristol Myers Squibb | Eliquis | Hematology | 3.42 | 4.14 |
Built for screening
Useful without pretending to be a terminal.
Whether you're comparing blockbuster drugs, tracking commercial launches, preparing investment research, or following quarterly earnings, the value is cleanup, normalization, and faster comparison.
Good for
Spotting launch ramps, comparing leading drug franchises, screening therapeutic areas, and saving time otherwise spent pulling numbers from filings, PDFs, and investor appendices.
Important limits
Company-reported product sales can vary by disclosure style. USD conversions are directional. This is research data, not investment advice or audited financial reporting.
FAQ
Small answers before you buy.
What format do I get?
An Excel workbook plus an interactive HTML preview. The workbook is the core deliverable.
How often is it updated?
The goal is to update after major quarterly reporting cycles, with priority on the companies and products investors care about most.
How accurate is the data?
It is built from company-reported product sales and cleaned for analysis. Because companies report differently, some judgment and normalization are involved.
Is this investment advice?
No. It is a structured research dataset for screening and analysis.
Why not just use filings?
You can. The point is saving the collection and cleanup time across earnings workbooks, presentations, PDFs, SEC filings, currencies, and reporting conventions.
Can I request a company or correction?
Yes. Email hello [at] drugsalesdb [dot] com for requests, corrections, or data questions.
Start with the spreadsheet. Let the charts point you where to look.
Track top drug franchises, launches, and product-sales momentum across major pharma companies in one clean workbook.